NYSE - Delayed Quote • USD
Bio-Rad Laboratories, Inc. (BIO)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 6:21 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 2.15 | 2.29 | 10.56 | 12 |
| Low Estimate | 2.02 | 2.03 | 10.25 | 11.45 |
| High Estimate | 2.29 | 2.49 | 10.96 | 12.38 |
| Year Ago EPS | 3.34 | 3 | 11.78 | 10.56 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 619.09M | 660.98M | 2.69B | 2.83B |
| Low Estimate | 612.1M | 645.1M | 2.68B | 2.8B |
| High Estimate | 629.16M | 676.7M | 2.71B | 2.86B |
| Year Ago Sales | 676.84M | 697.96M | 2.67B | 2.69B |
| Sales Growth (year/est) | -8.50% | -5.30% | 0.60% | 5.20% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 3.54 | 2.68 | 2.78 | 2.82 |
| EPS Actual | 3.34 | 3 | 2.33 | 3.1 |
| Difference | -0.2 | 0.32 | -0.45 | 0.28 |
| Surprise % | -5.60% | 11.90% | -16.20% | 9.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 2.15 | 2.29 | 10.56 | 12 |
| 7 Days Ago | 2.15 | 2.29 | 10.56 | 12 |
| 30 Days Ago | 2.66 | 2.49 | 10.7 | 12.15 |
| 60 Days Ago | 2.66 | 2.49 | 10.7 | 12.15 |
| 90 Days Ago | 3.28 | 2.92 | 11.57 | 13.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BIO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -35.60% | -- | -- | 2.60% |
| Next Qtr. | -23.70% | -- | -- | 13.40% |
| Current Year | -10.40% | -- | -- | 5.20% |
| Next Year | 13.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 17.80% | -- | -- | 11.11% |
| Past 5 Years (per annum) | 13.82% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | Citigroup: Buy to Neutral | 4/3/2024 |
| Maintains | UBS: Buy to Buy | 2/16/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 2/16/2024 |
| Initiated | UBS: Buy | 12/7/2023 |
| Maintains | Wells Fargo: Overweight to Overweight | 8/7/2023 |
| Maintains | RBC Capital: Outperform to Outperform | 8/4/2023 |
Related Tickers
BRKR Bruker Corporation
80.59
-1.96%
QDEL QuidelOrtho Corporation
39.69
-2.77%
PODD Insulet Corporation
164.17
-1.84%
EW Edwards Lifesciences Corporation
88.01
-0.68%
ZBH Zimmer Biomet Holdings, Inc.
119.75
-1.17%
INSP Inspire Medical Systems, Inc.
231.01
-1.36%
IART Integra LifeSciences Holdings Corporation
28.41
-3.30%
PEN Penumbra, Inc.
205.50
-0.32%
ALGN Align Technology, Inc.
310.50
-1.05%
MASI Masimo Corporation
135.24
-0.50%